Alnylam Pharmaceuticals | ALNY - Debt

Stock Price
331.24
Daily Change
-20.72 -5.89%
Monthly
-18.49%
Yearly
19.04%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $1.3B in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Agios Pharmaceuticals USD 48.76M 47.62M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 54.59B 1.62B Sep/2025
Arrowhead Research USD 366.28M 13.25M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.23B 192.99M Sep/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 32.02B 615M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Takeda JPY 4.85T 208B Dec/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025
Xencor USD 67.93M 86.45M Jun/2025